Literature DB >> 3756822

Carcinoma of the fallopian tube. Management and sites of failure.

E H McMurray, A J Jacobs, C A Perez, H M Camel, M S Kao, A Galakatos.   

Abstract

Thirty patients with adenocarcinoma of the fallopian tube, treated between 1950 and 1981, were studied. Median age was 55 years, and mean parity was 1.3. Bleeding or discharge occurred as a presenting complaint in 47% of patients, abdominal distention or mass in 50%, and pain in 30%. Lesions were staged using a system analogous to the International Federation of Gynecology and Obstetrics (FIGO) classification for ovarian carcinoma. Nine patients had Stage I disease; 11, Stage II; 7, Stage III; and 3, Stage IV. Histologic differentiation was Grade 1 in 39% of the patients, Grade 2 in 18%, and Grade 3 in 43%. Primary surgical treatment consisted of total abdominal hysterectomy and bilateral salpingectomy in 70% of the patients; 23% had more extensive surgery, whereas 13% had less extensive surgery. Three patients with Stage I tumors were treated with surgery alone, and the remainder received postoperative radiation, chemotherapy, or both. Survival was unrelated to grade, but highly dependent upon stage. Survival at 5 years was 56% for Stage I, 27% for Stage II, 14% for Stage III, and 0% for Stage IV. Four of five patients treated after surgery with a combination of cisplatin, doxorubicin, and cyclophosphamide (PAC) survived at least 3 years. Patterns of initial treatment failure showed 56% with a component of pelvic failure, 50% with a component of upper abdominal failure, and 44% with extraperitoneal metastases as a component of failure. These results suggest the need for aggressive postoperative adjuvant therapy targeted at upper abdominal and distant sites for metastasis in all lesions beyond Stage I.

Entities:  

Mesh:

Year:  1986        PMID: 3756822     DOI: 10.1002/1097-0142(19861101)58:9<2070::aid-cncr2820580918>3.0.co;2-3

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  Primary fallopian tube carcinoma: a clinicopathological analysis of a rare entity.

Authors:  Yu-Jin Koo; Kyoung-Shil Im; Yong-Soon Kwon; In-Ho Lee; Tae-Jin Kim; Kyung-Taek Lim; Ki-Heon Lee; Jae-Uk Shim; Jung-Eun Mok
Journal:  Int J Clin Oncol       Date:  2010-09-29       Impact factor: 3.402

Review 2.  Primary fallopian tube cancer: a review of the literature.

Authors:  A C Hellström
Journal:  Med Oncol       Date:  1998-04       Impact factor: 3.064

3.  Primary Adenocarcinoma of the Fallopian Tube: A Rare Entity.

Authors:  Ankita Singh; Sudha Prasad; Ashok Kumar; Renu Tanwar
Journal:  J Clin Diagn Res       Date:  2017-09-01

4.  Radical lymphadenectomy in the primary carcinoma of the fallopian tube.

Authors:  M Klein; A Rosen; M Lahousen; A Graf; N Vavra; A Beck
Journal:  Arch Gynecol Obstet       Date:  1993       Impact factor: 2.344

5.  Evaluation of adjuvant therapy after surgery for primary carcinoma of the fallopian tube.

Authors:  M Klein; A Rosen; M Lahousen; A Graf; N Vavra; B Pakisch; J Poschauko; A Beck; H Kucera
Journal:  Arch Gynecol Obstet       Date:  1994       Impact factor: 2.344

6.  Primary fallopian tube carcinoma--a retrospective survey of 51 cases. Austrian Cooperative Study Group for Fallopian Tube Carcinoma.

Authors:  M Klein; A Rosen; A Graf; M Lahousen; H Kucera; B Pakisch; N Vavra; A Beck
Journal:  Arch Gynecol Obstet       Date:  1994       Impact factor: 2.344

7.  Asymptomatic primary fallopian tube cancer: an unusual cause of axillary lymphadenopathy.

Authors:  N A Healy; S O Hynes; J Bruzzi; S Curran; M O'Leary; K J Sweeney
Journal:  Case Rep Obstet Gynecol       Date:  2011-12-11

8.  Primary carcinoma of the fallopian tube--a retrospective analysis of 115 patients. Austrian Cooperative Study Group for Fallopian Tube Carcinoma.

Authors:  A Rosen; M Klein; M Lahousen; A H Graf; A Rainer; N Vavra
Journal:  Br J Cancer       Date:  1993-09       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.